Effects of obesity on estradiol metabolism

Decreased formation of nonuterotropic metabolites

J. Schneider, H. L. Bradlow, G. Strain, J. Levin, Karl Anderson, J. Fishman

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Obesity is associated with an increased incidence of reproductive dysfunction and estrogen-linked diseases. In the present study, we have examined the principal oxidative biotransformation of estradiol in 13 obese premenopausal females and 10 obese males compared to those in 9 premenopausal female and 15 male controls. These studies were carried out using a recently devised, sensitive radiometric method which permits the assessment of the total in vivo oxidative metabolism of estradiol at specific sites (i.e. 17α, 16α, or C-2) on the steroid molecule. Our results indicate that obesity (>60% above ideal body weight) is associated with significant decreases in hydroxylation at C-2 in both sexes (P < 0.001 for females and P < 0.02 for males) and in oxidation at 17α in premenopausal females (P < 0.05) compared to that in age-matched, normal weight controls. Analysis of the plasma 3H 2O specific activity curves suggested a slight decrease in the rate of 17-oxidation in obese subjects. The extent of hydroxylation at 16α was not significantly affected by obesity. These metabolic alterations documented in obesity could result in a relative hyperestrogenic state, since, unlike the other estrogen metabolites, the 2-hydroxyestrogen compounds display relatively little peripheral estrogenic activity. This metabolic alteration on a prolonged basis might be contributory to the prevalence of certain hormonally related diseases in obese individuals.

Original languageEnglish (US)
Pages (from-to)973-978
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume56
Issue number5
StatePublished - 1983
Externally publishedYes

Fingerprint

Hydroxylation
Metabolites
Metabolism
Estradiol
Estrogens
Obesity
Weight control
Oxidation
Steroids
Plasmas
Ideal Body Weight
Molecules
Biotransformation
Weights and Measures
Incidence

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of obesity on estradiol metabolism : Decreased formation of nonuterotropic metabolites. / Schneider, J.; Bradlow, H. L.; Strain, G.; Levin, J.; Anderson, Karl; Fishman, J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 56, No. 5, 1983, p. 973-978.

Research output: Contribution to journalArticle

Schneider, J. ; Bradlow, H. L. ; Strain, G. ; Levin, J. ; Anderson, Karl ; Fishman, J. / Effects of obesity on estradiol metabolism : Decreased formation of nonuterotropic metabolites. In: Journal of Clinical Endocrinology and Metabolism. 1983 ; Vol. 56, No. 5. pp. 973-978.
@article{0f5df2c88a5b454eacd8a09524021278,
title = "Effects of obesity on estradiol metabolism: Decreased formation of nonuterotropic metabolites",
abstract = "Obesity is associated with an increased incidence of reproductive dysfunction and estrogen-linked diseases. In the present study, we have examined the principal oxidative biotransformation of estradiol in 13 obese premenopausal females and 10 obese males compared to those in 9 premenopausal female and 15 male controls. These studies were carried out using a recently devised, sensitive radiometric method which permits the assessment of the total in vivo oxidative metabolism of estradiol at specific sites (i.e. 17α, 16α, or C-2) on the steroid molecule. Our results indicate that obesity (>60{\%} above ideal body weight) is associated with significant decreases in hydroxylation at C-2 in both sexes (P < 0.001 for females and P < 0.02 for males) and in oxidation at 17α in premenopausal females (P < 0.05) compared to that in age-matched, normal weight controls. Analysis of the plasma 3H 2O specific activity curves suggested a slight decrease in the rate of 17-oxidation in obese subjects. The extent of hydroxylation at 16α was not significantly affected by obesity. These metabolic alterations documented in obesity could result in a relative hyperestrogenic state, since, unlike the other estrogen metabolites, the 2-hydroxyestrogen compounds display relatively little peripheral estrogenic activity. This metabolic alteration on a prolonged basis might be contributory to the prevalence of certain hormonally related diseases in obese individuals.",
author = "J. Schneider and Bradlow, {H. L.} and G. Strain and J. Levin and Karl Anderson and J. Fishman",
year = "1983",
language = "English (US)",
volume = "56",
pages = "973--978",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Effects of obesity on estradiol metabolism

T2 - Decreased formation of nonuterotropic metabolites

AU - Schneider, J.

AU - Bradlow, H. L.

AU - Strain, G.

AU - Levin, J.

AU - Anderson, Karl

AU - Fishman, J.

PY - 1983

Y1 - 1983

N2 - Obesity is associated with an increased incidence of reproductive dysfunction and estrogen-linked diseases. In the present study, we have examined the principal oxidative biotransformation of estradiol in 13 obese premenopausal females and 10 obese males compared to those in 9 premenopausal female and 15 male controls. These studies were carried out using a recently devised, sensitive radiometric method which permits the assessment of the total in vivo oxidative metabolism of estradiol at specific sites (i.e. 17α, 16α, or C-2) on the steroid molecule. Our results indicate that obesity (>60% above ideal body weight) is associated with significant decreases in hydroxylation at C-2 in both sexes (P < 0.001 for females and P < 0.02 for males) and in oxidation at 17α in premenopausal females (P < 0.05) compared to that in age-matched, normal weight controls. Analysis of the plasma 3H 2O specific activity curves suggested a slight decrease in the rate of 17-oxidation in obese subjects. The extent of hydroxylation at 16α was not significantly affected by obesity. These metabolic alterations documented in obesity could result in a relative hyperestrogenic state, since, unlike the other estrogen metabolites, the 2-hydroxyestrogen compounds display relatively little peripheral estrogenic activity. This metabolic alteration on a prolonged basis might be contributory to the prevalence of certain hormonally related diseases in obese individuals.

AB - Obesity is associated with an increased incidence of reproductive dysfunction and estrogen-linked diseases. In the present study, we have examined the principal oxidative biotransformation of estradiol in 13 obese premenopausal females and 10 obese males compared to those in 9 premenopausal female and 15 male controls. These studies were carried out using a recently devised, sensitive radiometric method which permits the assessment of the total in vivo oxidative metabolism of estradiol at specific sites (i.e. 17α, 16α, or C-2) on the steroid molecule. Our results indicate that obesity (>60% above ideal body weight) is associated with significant decreases in hydroxylation at C-2 in both sexes (P < 0.001 for females and P < 0.02 for males) and in oxidation at 17α in premenopausal females (P < 0.05) compared to that in age-matched, normal weight controls. Analysis of the plasma 3H 2O specific activity curves suggested a slight decrease in the rate of 17-oxidation in obese subjects. The extent of hydroxylation at 16α was not significantly affected by obesity. These metabolic alterations documented in obesity could result in a relative hyperestrogenic state, since, unlike the other estrogen metabolites, the 2-hydroxyestrogen compounds display relatively little peripheral estrogenic activity. This metabolic alteration on a prolonged basis might be contributory to the prevalence of certain hormonally related diseases in obese individuals.

UR - http://www.scopus.com/inward/record.url?scp=0020540295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020540295&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 973

EP - 978

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -